Two methodological advances aim to expand reliable genomic assays on limited clinical material. Ultra‑mild bisulfite sequencing (UMBS) reduces DNA damage during methylation profiling, boosting conversion efficiency at picogram to nanogram inputs and improving coverage for cfDNA and FFPE samples. Separately, EasyGeSe provides a benchmarking framework for genomic‑prediction methods to standardize performance comparisons across models and datasets. UMBS promises faster workflows with higher sensitivity for low‑input epigenetic studies and clinical diagnostics; EasyGeSe offers standardized metrics and datasets to accelerate development and selection of genomic predictors. Both tools address reproducibility and sample‑constraint bottlenecks that hamper translational genomics.